[Click eStock] "CorelineSoft, the Leading Player in the AI Medical Era 'CT Screening'"

ResearchAlum analyzed on the 13th that globally, only Coreline Soft and Siemens possess the technological capability to simultaneously screen for lung cancer, emphysema, and coronary artery calcification. It is expected that Coreline Soft will supply its solutions to European countries.

Moon Juseong, a researcher at ResearchAlum, stated, "AI-based CT medical imaging is rapidly emerging in cancer diagnosis," and explained, "According to the National Cancer Information Center, lung cancer accounted for 22.3% of cancer deaths in South Korea in 2022, ranking first."

He continued, "Because there are no pain cells inside the lungs, early cancer detection is difficult," adding, "CT scans use circular machines to capture hundreds of images from multiple angles, enabling early diagnosis of chest and abdominal cancers." Furthermore, he noted, "A drawback is the long screening time per patient," emphasizing, "Coreline Soft provides a solution that can shorten screening time through AI-based three-dimensional CT image analysis."

Researcher Moon analyzed, "The technological capability of lung cancer screening software depends on whether it can support multi-disease screening with a single scan," and stated, "Siemens is one of the four manufacturers dominating the CT market, with limited supply to the other three companies."

He explained, "To use AI-based screening solutions with technological capabilities from Philips, Canon, and GE, they must use Coreline Soft's solutions," and added, "By collaborating with Seoul National University Hospital, the Netherlands' 'iDNA', the United States' 'MGH', and China's 'Suhai', Coreline Soft has secured numerous exclusive datasets that only it can use, raising expectations for early market dominance."